Literature DB >> 8873231

Pentamidine aerosols and environmental contamination: health-care workers at risk.

J J Ros1, M C Langen, P C Stallen, A W Lenderink.   

Abstract

In our hospital safety guidelines are available for the handling of pentamidine in the day-care department, but no safety ventilation cabin is used because only one patient a day has been treated, The number of patients to be treated, however, is growing, resulting in the need to treat more than one patient a day. To determine the environmental contamination and exposure of health-care workers during and after aerosolised pentamidine treatment of more than one patient with the acquired immunodeficiency syndrome a day a high-performance liquid chromatographic method is used for the detection and quantification of pentamidine. High volume air samples were taken before, immediately after and the day after a treatment session of up to three patients. Also, sediment samples and personal air samples close to the mouth of the health-care workers were taken. Immediately after a treatment session the air in the room contains 1.0-99.7 micrograms pentamidine per m3 of air. Before and the morning after treatment no pentamidine could be detected in the air. Sediment samples vary in detectable amounts of pentamidine from < 5 to 1165 micrograms. pentamidine/cm2. The personal air samples also show a large variation in quantities of pentamidine: < 5-170 ng a filter. When large amounts of pentamidine in the high volume air samples are found high amounts of pentamidine on the sediment samples and the personal air samples are found as well. This means that the patients treated should be instructed well on how to use the nebulizer correctly and be monitored during treatment. Additional safety measures (for example the use of a safety ventilation cabin) should be taken when more than one patient is treated a day.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873231     DOI: 10.1007/bf00717731

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  8 in total

Review 1.  Problems and pitfalls in the assay of pentamidine. Implications for clinical use.

Authors:  B J Berger; L Henry; J E Hall; R R Tidwell
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Detection of inhaled pentamidine in health care workers.

Authors:  G C Smaldone; C Vinciguerra; J Marchese
Journal:  N Engl J Med       Date:  1991-09-19       Impact factor: 91.245

3.  Care-giver protection from exposure to aerosolized pharmacologic agents. Is it necessary?

Authors:  R M Kacmarek
Journal:  Chest       Date:  1991-10       Impact factor: 9.410

4.  Aerosolised pentamidine and public health.

Authors:  M A McDiarmid; D Jacobson-Kram
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

5.  Investigations on mutagenicity and genotoxicity of pentamidine and some related trypanocidal diamidines.

Authors:  I Stauffert; H Paulini; U Steinmann; H Sippel; C J Estler
Journal:  Mutat Res       Date:  1990-10       Impact factor: 2.433

6.  High-performance liquid chromatographic method for the quantification of several diamidine compounds with potential chemotherapeutic value.

Authors:  B J Berger; J E Hall; R R Tidwell
Journal:  J Chromatogr       Date:  1989-09-29

7.  Exposure of health care workers to aerosolized pentamidine.

Authors:  T G O'Riordan; G C Smaldone
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

8.  High-performance liquid chromatographic method for quantitation of pentamidine in blood serum.

Authors:  C M Dickinson; T R Navin; F C Churchill
Journal:  J Chromatogr       Date:  1985-11-29
  8 in total
  1 in total

1.  Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Authors:  Paul Zarogoulidis; Ellada Eleftheriadou; Iordanis Sapardanis; Vasiliki Zarogoulidou; Helliel Lithoxopoulou; Theodoros Kontakiotis; Nikolaos Karamanos; George Zachariadis; Maria Mabroudi; Athanasios Zisimopoulos; Kostantinos Zarogoulidis
Journal:  Invest New Drugs       Date:  2011-07-08       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.